These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1035 related items for PubMed ID: 17079256

  • 1. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM.
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [Abstract] [Full Text] [Related]

  • 2. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [Abstract] [Full Text] [Related]

  • 4. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
    D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A, Scognamiglio G, Russo MG, Calabrò R.
    Int J Cardiol; 2012 Mar 22; 155(3):378-82. PubMed ID: 21081251
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.
    Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J.
    Eur Respir J; 2004 Dec 22; 24(6):1007-10. PubMed ID: 15572546
    [Abstract] [Full Text] [Related]

  • 6. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.
    J Am Coll Cardiol; 2010 May 04; 55(18):1915-22. PubMed ID: 20430262
    [Abstract] [Full Text] [Related]

  • 7. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
    Douwes JM, Roofthooft MT, Van Loon RL, Ploegstra MJ, Bartelds B, Hillege HL, Berger RM.
    Heart; 2014 Feb 04; 100(3):224-30. PubMed ID: 24390161
    [Abstract] [Full Text] [Related]

  • 8. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, Mühler EG, Ewert P, Lange PE, Berger F, Schulze-Neick I.
    Eur J Clin Invest; 2006 Sep 04; 36 Suppl 3():32-8. PubMed ID: 16919008
    [Abstract] [Full Text] [Related]

  • 9. [Sildenafil therapy for pulmonary hypertension: a prospective study].
    Lu XL, Xiong CM, Shan GL, Liu ZH, Ni XH, Cheng XS, Gu Q, Zhao ZH, Zeng WJ, Zhu F, He JG.
    Zhonghua Jie He He Hu Xi Za Zhi; 2011 Jun 04; 34(6):419-23. PubMed ID: 21781512
    [Abstract] [Full Text] [Related]

  • 10. Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller.
    Kamata Y, Iwamoto M, Minota S.
    Lupus; 2007 Jun 04; 16(11):901-3. PubMed ID: 17971364
    [Abstract] [Full Text] [Related]

  • 11. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.
    Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM.
    J Heart Lung Transplant; 2005 Oct 04; 24(10):1626-31. PubMed ID: 16210140
    [Abstract] [Full Text] [Related]

  • 12. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.
    J Heart Lung Transplant; 2007 Apr 04; 26(4):363-9. PubMed ID: 17403478
    [Abstract] [Full Text] [Related]

  • 13. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL.
    Circulation; 2003 Oct 28; 108(17):2066-9. PubMed ID: 14568893
    [Abstract] [Full Text] [Related]

  • 14. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.
    Porhownik NR, Al-Sharif H, Bshouty Z.
    Can Respir J; 2008 Oct 28; 15(8):427-30. PubMed ID: 19107243
    [Abstract] [Full Text] [Related]

  • 15. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubin LJ.
    J Heart Lung Transplant; 2011 Dec 28; 30(12):1327-33. PubMed ID: 22055098
    [Abstract] [Full Text] [Related]

  • 16. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
    McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ.
    Am J Respir Crit Care Med; 2006 Dec 01; 174(11):1257-63. PubMed ID: 16946127
    [Abstract] [Full Text] [Related]

  • 17. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
    Hoeper MM.
    Eur Respir J; 2007 Mar 01; 29(3):432-4. PubMed ID: 17329488
    [No Abstract] [Full Text] [Related]

  • 18. The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension.
    Xu XQ, Jing ZC, Zhang JH, Wu Y, Wang Y, Jiang X, Wang ZX, Sun YG, Pu JL, Yang YJ.
    Hypertens Res; 2009 Oct 01; 32(10):911-5. PubMed ID: 19644505
    [Abstract] [Full Text] [Related]

  • 19. Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance.
    Porhownik NR, Myers R, Bshouty Z.
    Can Respir J; 2013 Oct 01; 20(2):111-5. PubMed ID: 23616968
    [Abstract] [Full Text] [Related]

  • 20. [Preliminary study on the efficacy and safety of oral sildenafil in pulmonary arterial hypertension in China].
    Xiong CM, He JG, Lu XL, Shan GL, Wu BX, Zhu XY, Wu GH, Zeng XF, Guo T, Liu ZH, Ni XH, Cheng XS, Gu Q, Zhao ZH, Tian HY, Li WM, Zhang DZ, Zhang C, Li MT, Liu HM, Guo YJ, Shen JY, Zhang WJ, Liu S, Zhou DX, Bao CD, Huang SA, Chen JY, Wu WF, Huang K, Li CL, Wang LH, He B.
    Zhonghua Yi Xue Za Zhi; 2011 Feb 15; 91(6):370-4. PubMed ID: 21418907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.